Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class

Executive Summary

One case of adjudicated arthropathy seen in halted Phase IIb study of anti-NGF candidate. Regeneron still hopes to advance fasinumab, partnered with Teva, into Phase III in osteoarthritis and chronic low back pain – but the second clinical hold for the class puts its future into even greater question.

Advertisement

Related Content

Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
Teva CEO Steps Down While An Integration Hangs In The Balance
Teva CEO Steps Down While An Integration Hangs In The Balance
Teva Hits Pause On Business Development, Even As Some Deals Stumble
Biopharma Quarterly Dealmaking Statistics, Q3 2016
Regeneron Partners NGF Antibody With Teva To Mitigate Risks
Deal Watch: Merck Hopes Moderna's Personalized Vaccines Can Increase Keytruda Patient Base
US FDA panel: Let anti-NGF studies move forward, despite 'severe' joint risks

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel